Results 101 to 110 of about 4,744 (194)

Response to: “Challenges in DPYD Test Implementation in Patients Treated with Fluoropyirimidines, is DPYD Genotype Arriving on Time?” [Response to Letter]

Pharmacogenomics and Personalized Medicine
Cristina Montrasio,1 Stefania Cheli,1 Emilio Clementi2,3 1Unit of Clinical Pharmacology, ASST Fatebenefratelli Sacco, L. Sacco University Hospital, Milan, Italy; 2Clinical Pharmacology Unit, Department of Biomedical and Clinical Sciences, L. Sacco University Hospital, Università degli Studi di Milano, Milan, Italy; 3Scientific Institute IRCCS ...
Cristina Montrasio, Stefania Cheli, Emilio Clementi   +2 more
openaire   +4 more sources

Real‐world implementation of DPYD and UGT1A1 pharmacogenetic testing in a community‐based cancer center

Clinical and Translational Science
We set out to demonstrate the feasibility of pharmacogenetic testing of DPYD and UGT1A1 and explore the clinical benefits in a community‐based cancer center.
Megan Muldoon, Mollie Beck, Nichlas Sebree, Robin Yoder, Stacey Ritter, Josiah D. Allen, Zuhair Alqahtani, Jaime Grund, Brooke Philips, Kristina Hesse, Nihal El Rouby   +10 more
doaj   +1 more source

Letter regarding Zhao et al. entitled “ gene polymorphisms are associated with risk and chemotherapy prognosis in pediatric patients with acute lymphoblastic leukemia”

Tumor Biology, 2017
Zhao et al. investigated the association between germline genetic polymorphisms in DPYD , the gene encoding dihydropyrimidine dehydrogenase, and (1) the risk of developing pediatric acute lymphoblastic leukemia and (2) outcome of acute lymphoblastic ...
Maarten J Deenen, Linda M Henricks, Gabe S Sonke, Jan HM Schellens, Didier Meulendijks   +4 more
doaj   +1 more source

Clinical relevance and side effects of DPYD variants DPYD*6 and Y186C in Chemotherapy fluoropyrimidine-based: A Systematic review

Fluoropyrimidine anticancer drug, Capecitabine and 5-Fluorouracil, is the widely used in treatment of different solid tumor types, such as colorectal, breast, and gastric cancers.
Patricia Moriel, Luciana de Aguiar Zollmann, Beatriz Possamai, EDER DE CARVALHO PINCINATO   +3 more
core   +1 more source

DPYD pathogenic variants associated with fluoropyrimidines toxicity [PDF]

, 2023
Background: Genetic variants in dihydropyrimidine dehydrogenase gene (DPYD) coding for the key enzyme (DPD) of fluoropyrimidines (FPs) catabolism. DPYD contributes to the development of severe FPs-related toxicity, and pathogenic DPYD variants detection ...
Burciaga-Flores, Carlos Horacio, Oliva-García, Noé Israel, Villarreal Alvarado, Francisco Javier, Vidal-Gutiérrez, Oscar, González-Guerrero, Juan Francisco, Gómez Ordaz, Valeria Jimena, Pérez-Ibave, Diana Cristina, Garza-Rodriguez, Maria de Lourdes, Cortes Alfaro, Jonatán Isaí, Ramos-Martínez, Irasema   +9 more
core  

Abstracts

Molecular Oncology, Volume 20, Issue S1, Page 1-692, August 2026.
Abstracts submitted to the ‘EACR 2026 Congress: Innovative Cancer Science’, from 08–11 June 2026 and accepted by the Congress Organising Committee are published in this Supplement of Molecular Oncology, an affiliated journal of the European Association for Cancer Research (EACR).
wiley   +1 more source

Abstract 4069: Trimethylation and acetylation of Histone H3K27 modulates 5-fluorouracil response by regulating DPYD expression

, 2017
The antimetabolite 5-fluorouracil (5-FU) is one of the most widely used chemotherapy drugs. Dihydropyrimidine dehydrogenase (DPD) initiates the catabolic degradation of 5-FU to inactive metabolites and is widely accepted as a major determinant of 5-FU ...
Rentian Wu, Erin E. Tapper, Calvin R. Jerde, Robert B. Diasio, Steven M. Offer, Qian Nie   +5 more
core   +1 more source

Clinical implications of a gain-of-function genetic polymorphism in DPYD (rs4294451) in colorectal cancer patients treated with fluoropyrimidines

Frontiers in Pharmacology
Dihydropyrimidine dehydrogenase (DPD, encoded by the DPYD gene) is the rate-limiting enzyme for the detoxification of fluoropyrimidines (FLs). Rs4294451 is a regulatory DPYD polymorphism that has recently been functionally characterized and associated ...
Elena De Mattia, Jerry Polesel, Lucia Scarabel, Erika Cecchin   +3 more
doaj   +1 more source

DPYD gene activity score (GAS) predicts dose-limiting toxicity in fluoropyrimidine-treated colorectal cancer patients

, 2018
Pre-treatment DPYD genotyping of a panel of 4-single nucleotide polymorphism (SNP) including DPYD*2A, DPYD*13, c.2846A>T and c.1236A>G-HapB3, has been strongly recommended by the current pharmacogenetics guidelines in order to avoid severe ...
Polesel Jerry, Guardascione Michela, Mini Enrico, Toffoli Giuseppe, Dalle Fratte Chiara, Berretta Massimiliano, Favaretto Adolfo, Dreussi Eva, Roncato Rossana, De Mattia Elena, Palazzari Elisa, Nobili Stefania, Foltran Luisa, Buonadonna Angela, Garziera Marica, Bignucolo Alessia, ECCA, FABRIZIO, Sartor Franca, De Paoli Antonino, Cecchin Erika, D’Andrea Mario, DALLE FRATTE, CHIARA, D'Andrea Mario, Ecca Fabrizio   +23 more
core   +1 more source

Discovering novel germline genetic variants linked to severe fluoropyrimidine-related toxicity in- and outside DPYD

Genome Medicine
Background The Alpe-DPD study (NCT02324452) demonstrated that prospective genotyping and dose-individualization using four alleles in DPYD (DPYD*2A/rs3918290, c.1236G > A/rs75017182, c.2846A > T/rs67376798 and c.1679 T > G/rs56038477) can mitigate the ...
Jonathan E. Knikman, Qinglian Zhai, Carin A. T. C. Lunenburg, Linda M. Henricks, Stefan Böhringer, Maaike van der Lee, Femke M. de Man, Steven M. Offer, Shikshya Shrestha, Geert-Jan Creemers, Arnold Baars, Vincent O. Dezentjé, Alexander L. T. Imholz, Frank J. F. Jeurissen, Johanna E. A. Portielje, Rob L. H. Jansen, Paul Hamberg, Helga J. Droogendijk, Miriam Koopman, Peter Nieboer, Marlène H. W. van de Poel, Caroline M. P. W. Mandigers, Ron H. N. van Schaik, Hans Gelderblom, Ron H. J. Mathijssen, Jan H. M. Schellens, Annemieke Cats, Henk-Jan Guchelaar, Jesse J. Swen   +28 more
doaj   +1 more source